




# 4<sup>TH</sup> ITALIAN SUMMIT ON PRECISION MEDICINE

*Presidents: Giuseppe Curigliano and Paolo Marchetti*

19<sup>th</sup> - 20<sup>th</sup> April 2024

Villa Aurelia - Largo di Porta San Pancrazio, 2 - Rome



# Rational

*Personalizing cancer medicine depends on the implementation of personalized diagnostics and therapeutics. Detailed genomic screening is likely to play a central role in this.*

*Personalized Medicine has been widely depicted as a striking innovation, that is able to reform the standard approach to disease management, replacing the one-size-fits-all scheme of medicine with a single-patient sized medical intervention. Personalized medicine promoters usually highlight its potential to combine a more effective health-care with costs containment, according to the following rules:*

- monitoring of disease risks and more effective prevention;*
- early intervention;*
- selection of optimal therapy;*
- reduction of trial-and-error prescribing and reduction of adverse drug reactions;*
- exclusion of unnecessary drugs;*
- therapeutic drug monitoring and disease progression/remission monitoring;*
- increased patient compliance with therapy.*

*But, in spite of expectations, many unsolved practical issues, from technical and scientific to ethical, legal and economic topics, are slowing down the translation of personalized medicine principles into medical practice. Furthermore, wide adoption of personalized strategies also has to deal with the peculiar rules, policy and reimbursement system of each country. Application of Personalized Medicine in the real world seems entangled by the unmet need to develop evidence-based guidelines.*

*The aim of the meeting, where we are expecting about 150 participants from Italy and Europe, is to discuss with principal key opinion leader about the future prospective of precision medicine and precision oncology and the application in the real world.*

# 19<sup>th</sup> April

- 13:00 - 13:30** Lunch
- 13:30 - 13:45** ***Opening and Welcome*** - **Giuseppe Curigliano, Paolo Marchetti**  
Welcome to the Congress
- 13:45 - 14:15** ***Keynote 1*** - **Patricia LoRusso**  
Understanding mechanisms of action of modern anticancer drugs
- 14:15 - 15:45** ***Educational session 1*** - **Chair: Alberto Bardelli**  
**Liquid biopsy in the clinic: Is it ready for prime time?**
- 14:15 - 14:35** Clinical utility of liquid biopsy in colorectal cancer  
**Alberto Bardelli**
- 14:35 - 14:55** Clinical utility of liquid biopsy in breast cancer  
**Umberto Malapelle**
- 14:55 - 15:15** Incorporating liquid biopsy in clinical practice to stratify the risk  
**Christian Rolfo**
- 15:15 - 15:35** European Liquid Biopsy Consortia: From discovery to clinical implementation  
**Klaus Pantel**
- 15:35 - 15:45** Q&A
- 15:45 - 16:30** Coffee break
- 16:30 - 18:00** ***Educational session 2*** - **Chairs: Giuseppe Curigliano, Andrea Botticelli**  
**The journey of antibody drug conjugates**
- 16:30 - 16:50** Refining our understanding of ADCs: targeting mutations  
**Christophe Massard**
- 16:50 - 17:10** Optimizing the safety of antibody-drug conjugates for the treatment of cancer  
**Giuseppe Curigliano**
- 17:10 - 17:30** Combining ADCs with other agents  
**Peter Schmid**
- 17:30 - 17:50** Novel antibody drug conjugates and beyond  
**Patricia LoRusso**
- 17:50 - 18:00** Q&A

- 08:45 - 10:15** ***Educational session 3*** - Chair: Dario Trapani  
**Designing innovative clinical trials**
- 08:45 - 09:05** Window of opportunity trials across subtypes  
**Barbara Pistilli**
- 09:05 - 09:25** Surrogate vs long term endpoint  
**Dario Trapani**
- 09:25 - 09:45** From maximum tolerated to optimal biological dose  
**Christophe Le Tourneau**
- 09:45 - 10:05** Decision making process for patients involved in clinical trials  
**Gabriella Pravettoni**
- 10:05 - 10:15** Q&A
- 10:15 - 10:45** Coffee break
- 10:45 - 12:15** ***Educational session 4*** - Chairs: Paolo Marchetti, Ruggero De Maria  
**Tumor Agnostic Drug Development**
- 10:45 - 11:05** Design of next generation precision medicine trials using artificial intelligence  
**Razelle Kurzrock**
- 11:05 - 11:25** Agnostic drug development  
**Vivek Subbiah**
- 11:25 - 11:45** Target identification in agnostic drug development  
**Giancarlo Pruneri**
- 11:45 - 12:05** Next generation sequencing role in precision medicine  
**Jeffrey Ross**
- 12:05 - 12:15** Q&A
- 12:15 - 13:15** Lunch
- 13:15 - 13:45** ***Keynote 2*** - Timothy A. Yap  
Targeting oxidative phosphorylation (OXPHOS) is a rational anticancer strategy

# 20<sup>th</sup> April

- 13:45 - 14:05** **Keynote 3 - Giuseppe Curigliano**  
Precision Medicine in advanced and early Breast Cancer
- 14:05 - 14:25** **Keynote 4 - Andrea Botticelli**  
Precision Immunotherapy
- 14:25 - 14:45** **Keynote 5 - Maurizio Simmaco**  
The pivotal role of functional biochemistry into Precision Medicine
- 14:45 - 15:05** **Keynote 6 - Nello Martini**  
Role of the Regulator into precision medicine
- 15:05 - 16:35** **Educational session 5 - Chairs: Paolo Marchetti, Giuseppe Curigliano**  
**Harmonizing Precision Medicine Recommendations**
- 15:05 - 15:25** Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers  
**Maria Fernanda Mosele**
- 15:25 - 15:45** Recommendations on clinical reporting of genomics test results  
**David Tamborero**
- 15:45 - 16:05** Group Recommendations on the Structure and Quality Indicators for Molecular Tumor Boards in Clinical Practice  
**Christoph Benedikt Westphalen**
- 16:05 - 16:15** Big Data platform ad AI  
**Annarosa Farina**
- 16:15 - 16:30** Q&A
- 16:30 - 16:45** Conclusions
- 16:45 - 17:00** Final evaluation test

# Speakers and Chairmen

**Alberto Bardelli - Turin (Italy)** - IFOM Scientific Director, Principal Investigator Genomics of Cancer and Targeted Therapies, Professor Dept of Oncology, University of Turin

**Andrea Botticelli - Rome (Italy)** - Professor of Oncology at La Sapienza University of Rome

**Giuseppe Curigliano - Milan (Italy)** - Professor of Medical Oncology, Department of Oncology and Hemato-Oncology, University of Milano. Director Division of Early Drug Development for Innovative Therapies, European Institute of Oncology - IRCCS

**Ruggero De Maria - Rome (Italy)** - Professor of General Pathology at Sacro Cuore University - President of the A.C.C. (Italian National Oncology Network)

**Annarosa Farina - Milan (Italy)** - Chief of IT Division IEO - European Institute of Oncology - IRCCS

**Razelle Kurzrock - Milwaukee, Wisconsin (USA)** - Center Associate Director, Professor of Medicine, Medical College of Wisconsin Cancer Center

**Christophe Le Tourneau - Paris (France)** - Head of the Department of Drug Development and Innovation (D3i) and Head and Neck Clinic - Institut Curie

**Patricia LoRusso - New Haven (USA)** - Amy and Joseph Perella Professor of Medicine (Medical Oncology); Chief, Experimental Therapeutics; Associate Cancer Center Director, Experimental Therapeutics, Yale Cancer Center University

**Umberto Malapelle - Naples (Italy)** - Chief Supervisor of the Predictive Molecular Pathology Laboratory of the Department of Public Health of the University Federico II

**Paolo Marchetti - Rome (Italy)** - Scientific Director, Istituto Dermopatico dell'Immacolata - IRCCS

**Nello Martini - Rome (Italy)** - President of the Ricerca e Salute Foundation

**Christophe Massard - Villejuif (France)** - Chief of the Drug Development Department (DITEP), Gustave Roussy

**Maria Fernanda Mosele - Paris (France)** - Researcher Department of Medical Oncology, Gustave Roussy, Villejuif

**Klaus Pantel - Hamburg (Germany)** - Chairman of the Institute of Tumour Biology at the University Medical Centre Hamburg-Eppendorf

**Barbara Pistilli - Paris (France)** - Researcher Department of Medical Oncology, Gustave Roussy, Villejuif

# Speakers and Chairmen

**Gabriella Pravettoni - Milan (Italy)** - Director, Applied Research Division for Cognitive and Psychological Science, IEO

**Giancarlo Pruneri - Milan (Italy)** - Head of Department of Pathology and Laboratory Medicine, Fondazione IRCCS, Istituto Nazionale Tumori, Professor in Pathology, University of Milan, School of Medicine; Editor-in-Chief Tumori Journal

**Christian Rolfo - New York (USA)** - Professor of Medicine, Associate Director of Clinical Research, Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai System & ICAHN School of Medicine, President of the International Society of Liquid Biopsy (ISLB)

**Jeffrey Ross - Syracuse (USA)** - Medical Director, Foundation Medicine, Departments of Pathology and Urology, Upstate Medical University

**Peter Schmid - London (U.K.)** - Clinical Director of the Breast Cancer Centre and honorary consultant medical oncologist at St. Bartholomew's Hospital

**Maurizio Simmaco - Rome (Italy)** - Professor of Molecular Biology, La Sapienza University

**Vivek Subbiah - Nashville (USA)** - Chief of Early-Phase Drug Development at Sarah Cannon Research Institute

**David Tamborero - Stockholm (Sweden)** - Senior Research Scientist Karolinska Institutet

**Dario Trapani - Houston (USA)** - Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

**Timothy A. Yap - Houston (USA)** - Head of Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

**Christoph Benedikt Westphalen - Munich (Germany)** Head "Molecular Diagnostics and Therapy Programme" and the "Molecular Tumour Board" at the University of Munich, Germany. Medical lead for early phase clinical trials in medical oncology



# General Information

## **Presidents:**

Giuseppe Curigliano and Paolo Marchetti

## **Congress Venue:**

Villa Aurelia - Largo di Porta San Pancrazio, 2 - Rome

CME Provider n. 4795

Didactika S.r.l.

Piazza della Trasfigurazione, 8/a - 00151 Rome

ref. n. 369299

CME Credits: 9,1

This event is open to biologists, medical doctors, surgeons, and psychologists.

## **Disciplines:**

Dermatology, Haematology, Gastroenterology, Internal medicine, Oncology, Radiotherapy, Gynaecology, Histology, Biochemistry, Pharmacology and Clinical Toxicology, Clinical Pathology; Medical genetics; General Surgery; Plastic and Reconstructive Surgery; Urology; General Medicine (Family Doctors); Palliative Care.

To obtain the CME credits, the participant should be present for at least 80% of the total duration of the Congress, fill in all the forms and pass the final CME test. At the end of the Congress, the organizing secretariat will issue a certificate of attendance.


## **Registration:**

Registration is free and necessary. To register for the Congress, please visit us at [www.didactika.it](http://www.didactika.it) or send the registration form by e-mail to: [info@didactika.it](mailto:info@didactika.it)

## **Registration includes:**

Access to all scientific sessions. Certificate of attendance.

This congress will be held in presence for a maximum of 150 participants.





Provider



Didactika srl



Ne.T.On. S.r.l.  
Segreteria Organizzativa

Thanks to the non conditioning contribution of:

